REGENERON

pharmaceuticals for treatment of diseases in humans, [ and/or animals; ] namely, diseases [ and/or injuries ] of the [ central and peripheral nervous systems; diseases and/or injuries to muscles; diseases and/or injuries to ] internal organs [ ; and dermal cancers derived from embryonic ectodermal and mesodermal layers ]